Skip to main content

Table 1 Basic characteristics of published DRMA in past 7 years

From: Improving the quality of reporting of systematic reviews of dose-response meta-analyses: a cross-sectional survey

Category by items All publications (N = 529)
No. of authors [median (first to third quartile)] 6 (4 to 8)
  ≤ 4 171 (32.33%)
 5 ~  8 278 2.55%)
  > 8 80 (15.12%)
Year of publish
 2011 35 (6.62%)
 2012 44 (8.32%)
 2013 56 (10.59%)
 2014 117 (22.12%)
 2015 120 (22.68%)
 2016 85 (16.07%)
 2017 (up to July-31) 72 (13.61%)
Database searched [median ((first to third quartile))] 2 (2 to 3)
  ≤ 1 61 (11.53%)
 2 ~  3 385 (72.78%)
  > 3 83 (15.69%)
Journal distribution (n = 174 for journal numbers)
 Specialist journal 410 (77.50%)
 General journal 119 (22.50%)
Methodologist involved
 Yes 349 (65.97%)
 No 180 (34.03%)
Design of source study
 Cohort 318 (60.11%)
 Case-control 7 (1.32%)
 Cross-section 3 (0.57%)
 Mixed 199 (37.62%)
 CCT and RCT 2 (0.38%)
Classification of subject
 Epidemiology 525 (99.24%)
 Intervention 1 (0.19%)
 Prognosis 2 (0.38%)
 Diagnose 1 (0.19%)
Primary outcome
 Cancer 260 (49.15%)
 CVD 118 (22.31%)
 Type 2 Diabetes 45 (8.51%)
 Fracture and Osteoarthritis 21 (3.97%)
 CVD and Cancer/Diabetes 13 (2.46%)
 Metabolic Syndrome or Obesity 13 (2.46%)
 Pregnancy Outcomes (e.g. neonatal death, low birth weight) 12 (2.27%)
 Dementia/Cognitive impairment/Alzheimer’s Disease/Parkinson’s disease 12 (2.27%)
 Depression 6 (1.13%)
 Digestive tract disease (e.g. pancreatitis, gallbladder disease) 12 (2.27%)
 Urinary System disease (e.g. urolithiasis) 6 (1.13%)
 Others (e.g. Cataract, Gout) 12 (2.27%)
No. of included studies [median ((first to third quartile))] 14 (10 to 21)
  ≤ 10 151 (28.54%)
 11 ~  21 247 (46.69%)
  > 21 130 (24.57%)
 Missing 1 (0.19%)
Region
 Asian 350 (66.16%)
 European 129 (24.39%)
 America 47 (8.88%)
 Australia 3 (0.57%)
Reporting checklist
 PRISMA 109 (20.60%)
 MOOSE 204 (38.56%)
 PRISMA + MOOSE 31 (5.86%)
 Other 6 (1.13%)
 None 179 (33.84%)
Model used in trend approximationa
 RCS regression 295 (55.77%)
 FP regression 61 (11.53%)
 Other non-linear regression 21 (3.97%)
 Linear 152 (28.73%)
Funding
 Yes 337 (63.71%)
 No 54 (10.21%)
 Not reported 138 (26.09%)
  1. aRCS restricted cubic spline, FP fractional polynomial; other non-linear regression including natural cubic spline, quadratic polynomial, et al.